A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2012
At a glance
- Drugs Entecavir; Hepatitis B vaccine recombinant; Interleukin-7; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions
- Acronyms CONVERT
- Sponsors Revimmune SAS
- 17 Oct 2012 Planned end date changed from 1 Nov 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 17 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Dec 2009 New trial record